Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis


24 Jul 2019 11:48 Ricerca


Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions.

Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines.

In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.

Inserito da segreteria SIDeMaST

Approfondimenti

FonteUS National Library of Medicine
Titolo originaleEmerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
AutoriChiricozzi, De Simone, Fossati, Peris.
Link fonteLink articolo originale
Argomenti correlati psoriasi psoriasi artropatica

SIDeMaST è su Facebook

Segui la pagina e diffondi la cultura dermatologica condividendo i contenuti.

Ti è piaciuto questo contenuto?